A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Clinical trial NCT04047290 · COMPLETED

Trial details

NCT number: NCT04047290
Sponsor: Akesobio Australia Pty Ltd
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplasms Malignant

Start date: 2019-09-20
Primary completion: 2024-02-27
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.